User profiles for Mohamad Yamani
 | Mohamad YamaniProfessor of Medicine, Mayo Clinic Verified email at mayo.edu Cited by 3540 |
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
Background Cardiac muscle hypercontractility is a key pathophysiological abnormality in
hypertrophic cardiomyopathy, and a major determinant of dynamic left ventricular outflow tract (…
hypertrophic cardiomyopathy, and a major determinant of dynamic left ventricular outflow tract (…
Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis
CORRESPONDENCE index ([(1− global extracellular volume fraction)× LV mass]/body
surface index) decreased with mavacamten (− 14.1 [9.5] g/m2) versus no change in placebo (− …
surface index) decreased with mavacamten (− 14.1 [9.5] g/m2) versus no change in placebo (− …
Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac …
…, PM McCarthy, JB Young, MH Yamani - The Journal of heart and …, 2004 - Elsevier
BACKGROUND: It is possible, but unproven, that hepatitis C (HCV) infection accelerates
atherosclerosis. We evaluated the hypothesis that donor HCV seropositivity predicts mortality …
atherosclerosis. We evaluated the hypothesis that donor HCV seropositivity predicts mortality …
Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: hemodynamic efficacy, clinical outcome, and …
Background The use of parenteral positive inotropic agents still remains a major component
of therapy for patients with advanced decompensated congestive heart failure (CHF). …
of therapy for patients with advanced decompensated congestive heart failure (CHF). …
Hypogammaglobulinemia and infection risk in solid organ transplant recipients
S Mawhorter, MH Yamani - Current opinion in organ …, 2008 - journals.lww.com
… Mawhorter, Steven a ; Yamani, Mohamad H b … Yamani, MD, Department of Cardiology, Mayo
Clinic, Davis 7E, 4500 San Pablo Road, Jacksonville, FL 32225, USA Tel: +1 904 953 7279; fax …
Clinic, Davis 7E, 4500 San Pablo Road, Jacksonville, FL 32225, USA Tel: +1 904 953 7279; fax …
Molecular testing in the management of cardiac transplant recipients: initial clinical experience
…, ER Rodriguez, DO Taylor, MH Yamani… - The Journal of heart …, 2006 - jhltonline.org
Gene expression profiling (GEP) has recently been introduced as a new modality for
cardiac allograft rejection monitoring. The test uses real-time polymerase chain reaction (PCR) …
cardiac allograft rejection monitoring. The test uses real-time polymerase chain reaction (PCR) …
Improved survival after acute myocardial infarction complicated by cardiogenic shock with circulatory support and transplantation: comparing aggressive intervention …
BACKGROUND: The prognosis for patients with myocardial infarction has steadily improved,
but remains poor for those developing cardiogenic shock. Utilization of re-vascularization, …
but remains poor for those developing cardiogenic shock. Utilization of re-vascularization, …
Detecting cardiomyopathies in pregnancy and the postpartum period with an electrocardiogram-based deep learning model
Aims Cardiovascular disease is a major threat to maternal health, with cardiomyopathy
being among the most common acquired cardiovascular diseases during pregnancy and the …
being among the most common acquired cardiovascular diseases during pregnancy and the …
Chemokine and chemokine receptor gene expression indicates acute rejection of human cardiac transplants1
NM Fahmy, MH Yamani, RC Starling, NB Ratliff… - …, 2003 - journals.lww.com
Background. Factors directing T-cell infiltration into allografts during acute rejection remain
poorly defined. Chemokines have been shown to mediate leukocyte recruitment into …
poorly defined. Chemokines have been shown to mediate leukocyte recruitment into …
Myocardial ischemic-fibrotic injury after human heart transplantation is associated with increased progression of vasculopathy, decreased cellular rejection and poor …
MH Yamani, SA Haji, RC Starling, EM Tuzcu… - Journal of the American …, 2002 - jacc.org
Objectives : We sought to assess the influence of peritransplant ischemia and fibrosis on the
development of allograft vasculopathy, acute cellular rejection and long-term outcome. …
development of allograft vasculopathy, acute cellular rejection and long-term outcome. …